Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary MATEON’S PHASE 2 GLOBAL STUDY FOR OT-101/ TGF-β INHIBITOR AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN ARGENTINA.
AGOURA HILLS, Calif. , Oct. 19, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (“Mateon” or the “Company”) (OTCQB:MATN) announced today the receipt of approval from Republica Argentina – Poder Ejecutivo Nacional, the regulatory agency of Argentina, to initiate the Company’s Phase 2 clinical
View HTML
Toggle Summary MATEON TO PARTICIPATE IN MERIDIAN CLINICAL TRIALS SUMMIT
AGOURA HILLS, California , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that Dr. Vuong Trieu , President and CEO of Mateon, will present clinical updates at Meridian
View HTML
Toggle Summary MATEON TO PARTICIPATE IN BIO INVESTOR FORUM DIGITAL
AGOURA HILLS, California , Oct. 12, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that Dr. Vuong Trieu , President and CEO of Mateon, will present a company overview and host
View HTML
Toggle Summary MATEON ANNOUNCES FIRST PATIENT ENROLLED IN ARTI-19: A MULTICENTER INTERVENTIONAL STUDY OF ARTISHIELD™ AGAINST COVID-19
TOP-LINE DATA ANTICIPATED IN FOURTH QUARTER 2020 AGOURA HILLS, California , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced the first patient enrolled this week in its Phase IV study
View HTML
Toggle Summary MATEON THERAPEUTICS TO INITIATE COMMERCIALIZATION OF ARTISHIELD™.
AGOURA HILLS, Calif. , Oct. 05, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, today announced that ArtiShield TM is now approved for manufacture and marketing by the Ministry of AYUSH (Ayurveda, Yoga and
View HTML
Toggle Summary OT-101 PRESENTATION AT PHARMA FORUM 2020
AGOURA HILLS, Calif. , Sept. 21, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that on September 21, 2020 , Dr. Vuong Trieu , CEO of Mateon, will be presenting as Webinar “Trabedersen-Drug
View HTML
Toggle Summary FDA Granted Pediatric Disease Designation for OXi-4503
-Treatment of acute myeloid leukemia (AML) due to genetic mutations that disproportionately affect pediatric patients AGOURA HILLS, Calif. , Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTCQB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced
View HTML
Toggle Summary MATEON’S GLOBAL STUDY FOR ARTEMISININ INTERVENTION AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN INDIA.
AGOURA HILLS, Calif. , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that its global study based on its ARTI-19 protocol for Artemisinin Intervention against COVID-19 has been
View HTML
Toggle Summary MATEON THERAPEUTICS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS
AGOURA HILLS, Calif. , Aug. 17, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTC.QB: MATN), a leading developer of TGF-β therapeutics, announced financial results for the second quarter ended June 30, 2020 . Unless otherwise stated, all comparisons are for the second quarter of 2020 compared to
View HTML
Toggle Summary MATEON THERAPEUTICS AND ABIOGENESIS TO INITIATE CLINICAL STUDY TO TEST ARTEMISININ AS A TREATMENT FOR COVID-19 IN INDIA
AGOURA HILLS, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, will be working together with Abiogenesis to initiate ARTI-19 randomized, controlled, multi-site India clinical study of Artemisinin against COVID-19.
View HTML